Latest FY 2025 Earnings Snapshot

Concentra Group Holdings Parent (CON) has just wrapped up FY 2025 with Q4 revenue of US$539.1 million and Basic EPS of US$0.27, setting the tone for how the market will read its profit story at a share price of US$23.60. The company has seen quarterly revenue move from US$465.0 million in Q4 FY 2024 to US$539.1 million in Q4 FY 2025. Over that same period, Basic EPS shifted from US$0.17 to US$0.27, setting up a picture where top line and per share earnings trends feed directly into how investors judge the resilience of margins.

See our full analysis for Concentra Group Holdings Parent.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the widely followed narratives around growth, profitability and risk.

Margins Under Pressure At 7.6%

• Over the last 12 months, Concentra generated US$2.2b in revenue with a 7.6% net profit margin, compared with 8.8% a year earlier and trailing 12 month net income of US$164.2 million.
• Consensus narrative points to long term margin upside from clinic expansion and digital tools, yet the current 7.6% margin and recent year on year earnings decline of about 6.3% a year highlight that margin improvement is not showing up in the trailing numbers so far.
  • Supporters often reference acquisitions and telemedicine as margin drivers, but trailing net income of US$164.2 million is below the US$166.3 million level a year earlier, which does not yet back that bullish timing.
  • Forecasts for revenue growth of about 6.2% per year and earnings growth of roughly 12.1% per year sit alongside this lower margin base, so future improvement would need to come from both higher revenue and better cost control.

On today’s numbers, margin trends matter just as much as revenue growth for the long term story in the bullish case, so it is worth seeing how supporters frame that path in more detail 🐂 Concentra Group Holdings Parent Bull Case

Valuation Gap Versus DCF Fair Value

• With the stock at US$23.60 and a stated DCF fair value of US$66.32, the shares trade about 64.4% below that modelled value, and at a P/E of 18.5x versus 19x for peers and 22.4x for the wider US Healthcare industry.
• Bears focus on the 5 year annual earnings decline of about 6.3% and the drop in net margin from 8.8% to 7.6% as reasons the discount could reflect real business risk rather than just mispricing.
  • Critics highlight that operating cash flow does not fully cover debt and that leverage, measured at 3.8x net debt to EBITDA in the broader commentary, can limit flexibility even if the P/E looks slightly below sector levels.
  • Analysts are still setting a US$29.00 target, about 22.9% above the current US$23.60 price, which sits between the more cautious earnings trend and the much higher DCF fair value, so investors need to weigh which signal they trust more.

For anyone worried that the discount only exists because of genuine balance sheet and earnings risks, it can help to see how skeptics build their case around these same figures 🐻 Concentra Group Holdings Parent Bear Case

Earnings Quality Versus Growth Expectations

• Trailing 12 month Basic EPS stands at US$1.28 with net income of US$164.2 million on US$2.2b of revenue, and analysts are forecasting earnings growth of roughly 12.1% per year and revenue growth of about 6.2% per year from here.
• Consensus narrative talks about steady demand drivers such as employer compliance needs and clinic expansion supporting future growth, yet the data also shows earnings have declined about 6.3% annually over the last five years, so the market is weighing a higher quality but slower recent track record against those forward looking assumptions.
  • Supporters point to higher visit volumes and additional services as drivers for the forecast US$234.4 million earnings by around 2029, compared with US$164.2 million today, but the step up would require both the projected margin increase from 7.6% to 9.0% and the assumed 6.5% annual revenue growth to play out.
  • At the current US$23.60 share price, agreeing with the US$29.00 target means expecting the company to reach roughly US$2.6b of revenue and trade on a 19.7x P/E by that time, which is below the 24.9x P/E currently cited for the US Healthcare industry in the broader analysis.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Concentra Group Holdings Parent on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With bulls and bears both making strong arguments, you do not have to sit on the sidelines. Check the full picture of 4 key rewards and 1 important warning sign.

See What Else Is Out There

Concentra Group Holdings Parent is contending with thinner 7.6% net margins, a margin drop from 8.8%, and earnings that have declined about 6.3% annually.

If you are concerned about those weaker trends, it is worth checking companies with stronger balance sheets and earnings support using the solid balance sheet and fundamentals stocks screener (44 results) to spot ideas that may better match your risk comfort.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.